Corrigendum to “Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma” (Molecular Therapy (2016) 24(8) (1435–1443) (S152500161633595X) (10.1038/mt.2016.134));Enhancing antitumor immune responses by optimized combinations of cell-penetrating peptide-based vaccines and adjuvants

Molecular Therapy

Volumn 24, Issue 9, 2016, Pages 1675-1685

  Belnoue, Elodie ^a   Di Berardino Besson, Wilma ^b   Gaertner, Hubert ^c   Carboni, Susanna ^a   Dunand Sauthier, Isabelle ^c   Cerini, Fabrice ^c   Suso Inderberg, Else Marit ^d   Wälchli, Sébastien ^d   König, Stéphane ^c   Salazar, Andres M ^e   Hartley, Oliver ^c   Dietrich, Pierre Yves ^b   Walker, Paul R ^b   Derouazi, Madiha ^a  

^a C/o Fondation pour Recherches Médicales ^*  (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e Oncovir   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; CANCER VACCINE; CELL PENETRATING PEPTIDE; EPITOPE; PEPTIDE VACCINE; BZLF1 PROTEIN, HERPESVIRUS 4, HUMAN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOLOGICAL ADJUVANT; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CIRCULAR DICHROISM; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION; TUMOR IMMUNITY; ANIMAL; CHEMISTRY; CROSS PRESENTATION; DENDRITIC CELL; DISEASE MODEL; HUMAN; IMMUNOLOGY; METABOLISM; MORTALITY; NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; CIRCULAR DICHROISM; CROSS-PRIMING; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; EPITOPES, T-LYMPHOCYTE; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MICE; NEOPLASMS; TRANS-ACTIVATORS; TREATMENT OUTCOME; VACCINATION;

EID: 84981252323     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2016.196     Document Type: Erratum

References (37)

1. Melero, I, Gaudernack, G, Gerritsen, W, Huber, C, Parmiani, G, Scholl, S, et al. (2014). Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol 11: 509-524
2. Marusyk, A, and Polyak, K. (2010). Tumor heterogeneity: causes, and consequences. Biochim Biophys Acta 1805: 105-117
3. Rabinovich, GA, Gabrilovich, D, and Sotomayor, EM. (2007). Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25: 267-296
4. Wu, AA, Drake, V, Huang, HS, Chiu, S, and Zheng, L. (2015). Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology 4: e1016700
5. Dunn, GP, Bruce, AT, Ikeda, H, Old, LJ, and Schreiber, RD. (2002). Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998
6. Guo, C, Manjili, MH, Subjeck, JR, Sarkar, D, Fisher, PB, and Wang, XY. (2013). Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res 119: 421-475
7. van Montfoort, N, Camps, MG, Khan, S, Filippov, DV, Weterings, JJ, Griffith, JM, et al. (2009). Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity. Proc Natl Acad Sci USA 106: 6730-6735
8. Toes, RE, Offringa, R, Blom, RJ, Melief, CJ, and Kast, WM. (1996). Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci USA 93: 7855-7860
9. Rosalia, RA, Quakkelaar, ED, Redeker, A, Khan, S, Camps, M, Drijfhout, JW, et al. (2013). Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation, and T-cell activation. Eur J Immunol 43: 2554-2565
10. Derouazi, M, Di Berardino-Besson, W, Belnoue, E, Hoepner, S, Walther, R, Benkhoucha, M, et al. (2015). Novel cell-penetrating peptide-based vaccine induces robust CD4+, and CD8+ T cell-mediated antitumor immunity. Cancer Res 75: 3020-3031
11. Copolovici, DM, Langel, K, Eriste, E, and Langel, U. (2014). Cell-penetrating peptides: design, synthesis, and applications. ACS Nano 8: 1972-1994
12. Milletti, F. (2012). Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov Today 17: 850-860
13. Frankel, AD, and Pabo, CO. (1988). Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55: 1189-1193
14. Tacken PJ, Joosten B, Reddy A, Wu D, Eek A, Laverman P, et al. (2008). No advantage of cell-penetrating peptides over receptor-specific antibodies in targeting antigen to human dendritic cells for cross-presentation. J Immunol 180: 7687-7696
15. Joliot, A, Pernelle, C, Deagostini-Bazin, H, and Prochiantz, A. (1991). Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci USA 88: 1864-1868
16. Derossi, D, Joliot, AH, Chassaing, G, and Prochiantz, A. (1994). The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269: 10444-10450
17. Deshayes, S, Decaffmeyer, M, Brasseur, R, and Thomas, A. (2008). Structural polymorphism of two CPP: an important parameter of activity. Biochim Biophys Acta 1778: 1197-1205
18. Eiriksdottir, E, Konate, K, Langel, U, Divita, G, and Deshayes, S. (2010). Secondary structure of cell-penetrating peptides controls membrane interaction, and insertion. Biochim Biophys Acta 1798: 1119-1128
19. Rothe, R, Liguori, L, Villegas-Mendez, A, Marques, B, Grunwald, D, Drouet, E, et al. (2010). Characterization of the cell-penetrating properties of the Epstein-Barr virus ZEBRA trans-activator. J Biol Chem 285: 20224-20233
20. Matsumoto, R, Okochi, M, Shimizu, K, Kanie, K, Kato, R, and Honda, H. (2015). Effects of the properties of short peptides conjugated with cell-penetrating peptides on their internalization into cells. Sci Rep 5: 12884
21. Greenfield, NJ. (1996). Methods to estimate the conformation of proteins, and polypeptides from circular dichroism data. Anal Biochem 235: 1-10
22. Hassan, SB, Sorensen, JF, Olsen, BN, and Pedersen, AE. (2014). Anti-CD40-mediated cancer immunotherapy: an update of recent, and ongoing clinical trials. Immunopharmacol Immunotoxicol 36: 96-104
23. Trumpfheller, C, Caskey, M, Nchinda, G, Longhi, MP, Mizenina, O, Huang, Y, et al. (2008). The microbial mimic poly IC induces durable, and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci USA 105: 2574-2579
24. Longhi, MP, Trumpfheller, C, Idoyaga, J, Caskey, M, Matos, I, Kluger, C, et al. (2009). Dendritic cells require a systemic type I interferon response to mature, and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 206: 1589-1602
25. Shibagaki, N, and Udey, MC. (2002). Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes, and elicit antitumor immunity. J Immunol 168: 2393-2401
26. Di Pisa, M, Chassaing, G, and Swiecicki, JM. (2015). When cationic cell-penetrating peptides meet hydrocarbons to enhance in-cell cargo delivery. J Pept Sci 21: 356-369
27. Qian, Z, Dougherty, PG, and Pei, D. (2015). Monitoring the cytosolic entry of cellpenetrating peptides using a pH-sensitive fluorophore. Chem Commun (Camb) 51: 2162-2165
28. Shibagaki, N, and Udey, MC. (2003). Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma. Eur J Immunol 33: 850-860
29. Woo, SJ, Kim, CH, Park, MY, Kim, HS, Sohn, HJ, Park, JS, et al. (2008). Coadministration of carcinoembryonic antigen, and HIV TAT fusion protein with CpGoligodeoxynucleotide induces potent antitumor immunity. Cancer Sci 99: 1034-1039
30. Park, JS, Kim, HS, Park, HM, Kim, CH, and Kim, TG. (2011). Efficient induction of anti-tumor immunity by a TAT-CEA fusion protein vaccine with poly(I: C) in a murine colorectal tumor model. Vaccine 29: 8642-8648
31. Apostolopoulos, V, Pouniotis, DS, van Maanen, PJ, Andriessen, RW, Lodding, J, Xing, PX, et al. (2006). Delivery of tumor associated antigens to antigen presenting cells using penetratin induces potent immune responses. Vaccine 24: 3191-3202
32. Santiago-Raber, ML, Baccala, R, Haraldsson, KM, Choubey, D, Stewart, TA, Kono, DH, et al. (2003). Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 197: 777-788
33. Landmann, S, Muhlethaler-Mottet, A, Bernasconi, L, Suter, T, Waldburger, JM, Masternak, K, et al. (2001). Maturation of dendritic cells is accompanied by rapid transcriptional silencing of class II transactivator (CIITA) expression. J Exp Med 194: 379-391
34. Hartley, O, Gaertner, H, Wilken, J, Thompson, D, Fish, R, Ramos, A, et al. (2004). Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors. Proc Natl Acad Sci USA 101: 16460-16465
35. Miyahira, Y, Murata, K, Rodriguez, D, Rodriguez, JR, Esteban, M, Rodrigues, MM, et al. (1995). Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J Immunol Methods 181: 45-54
36. Almasbak, H, Rian, E, Hoel, HJ, Pule, M, Walchli, S, Kvalheim, G, et al. (2011). Transiently redirected T cells for adoptive transfer. Cytotherapy 13: 629-640
37. Walchli, S, Loset, GA, Kumari, S, Johansen, JN, Yang, W, Sandlie, I, et al. (2011). A practical approach to T-cell receptor cloning, and expression. PLoS One 6: e27930